Cargando…

Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein

[Image: see text] The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably rapid and inexpensive and can be rapidly mass-produced, but for sufficiently accurate performance, they req...

Descripción completa

Detalles Bibliográficos
Autores principales: Cate, David M., Bishop, Joshua D., Hsieh, Helen V., Glukhova, Veronika A., Alonzo, Luis F., Hermansky, H. Gleda, Barrios-Lopez, Brianda, Grant, Benjamin D., Anderson, Caitlin E., Spencer, Ethan, Kuhn, Samantha, Gallagher, Ryan, Rivera, Rafael, Bennett, Crissa, Byrnes, Samantha A., Connelly, John T., Dewan, Puneet K., Boyle, David S., Weigl, Bernhard H., Nichols, Kevin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482319/
https://www.ncbi.nlm.nih.gov/pubmed/34608447
http://dx.doi.org/10.1021/acsomega.1c01253
_version_ 1784576876787793920
author Cate, David M.
Bishop, Joshua D.
Hsieh, Helen V.
Glukhova, Veronika A.
Alonzo, Luis F.
Hermansky, H. Gleda
Barrios-Lopez, Brianda
Grant, Benjamin D.
Anderson, Caitlin E.
Spencer, Ethan
Kuhn, Samantha
Gallagher, Ryan
Rivera, Rafael
Bennett, Crissa
Byrnes, Samantha A.
Connelly, John T.
Dewan, Puneet K.
Boyle, David S.
Weigl, Bernhard H.
Nichols, Kevin P.
author_facet Cate, David M.
Bishop, Joshua D.
Hsieh, Helen V.
Glukhova, Veronika A.
Alonzo, Luis F.
Hermansky, H. Gleda
Barrios-Lopez, Brianda
Grant, Benjamin D.
Anderson, Caitlin E.
Spencer, Ethan
Kuhn, Samantha
Gallagher, Ryan
Rivera, Rafael
Bennett, Crissa
Byrnes, Samantha A.
Connelly, John T.
Dewan, Puneet K.
Boyle, David S.
Weigl, Bernhard H.
Nichols, Kevin P.
author_sort Cate, David M.
collection PubMed
description [Image: see text] The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably rapid and inexpensive and can be rapidly mass-produced, but for sufficiently accurate performance, they require highly optimized antibodies and assay conditions. We used an automated liquid handling system, customized to handle arrays of lateral flow (immuno)assays (LFAs) in a high-throughput screen, to identify anti-nucleocapsid antibodies that will perform optimally in an LFA. We tested 1021 anti-nucleocapsid antibody pairs as LFA capture and detection reagents with the goal of highlighting pairs that have the greatest affinity for the nucleocapsid protein of SARS-CoV-2 within the LFA format. In contrast to traditional antibody screening methods (e.g., ELISA, bio-layer interferometry), the method described here integrates real-time reaction kinetics with transport in, and immobilization directly onto, nitrocellulose. We have identified several candidate antibody pairs that are suitable for further development of an LFA for SARS-CoV-2.
format Online
Article
Text
id pubmed-8482319
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-84823192021-09-30 Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein Cate, David M. Bishop, Joshua D. Hsieh, Helen V. Glukhova, Veronika A. Alonzo, Luis F. Hermansky, H. Gleda Barrios-Lopez, Brianda Grant, Benjamin D. Anderson, Caitlin E. Spencer, Ethan Kuhn, Samantha Gallagher, Ryan Rivera, Rafael Bennett, Crissa Byrnes, Samantha A. Connelly, John T. Dewan, Puneet K. Boyle, David S. Weigl, Bernhard H. Nichols, Kevin P. ACS Omega [Image: see text] The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably rapid and inexpensive and can be rapidly mass-produced, but for sufficiently accurate performance, they require highly optimized antibodies and assay conditions. We used an automated liquid handling system, customized to handle arrays of lateral flow (immuno)assays (LFAs) in a high-throughput screen, to identify anti-nucleocapsid antibodies that will perform optimally in an LFA. We tested 1021 anti-nucleocapsid antibody pairs as LFA capture and detection reagents with the goal of highlighting pairs that have the greatest affinity for the nucleocapsid protein of SARS-CoV-2 within the LFA format. In contrast to traditional antibody screening methods (e.g., ELISA, bio-layer interferometry), the method described here integrates real-time reaction kinetics with transport in, and immobilization directly onto, nitrocellulose. We have identified several candidate antibody pairs that are suitable for further development of an LFA for SARS-CoV-2. American Chemical Society 2021-09-21 /pmc/articles/PMC8482319/ /pubmed/34608447 http://dx.doi.org/10.1021/acsomega.1c01253 Text en © 2021 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Cate, David M.
Bishop, Joshua D.
Hsieh, Helen V.
Glukhova, Veronika A.
Alonzo, Luis F.
Hermansky, H. Gleda
Barrios-Lopez, Brianda
Grant, Benjamin D.
Anderson, Caitlin E.
Spencer, Ethan
Kuhn, Samantha
Gallagher, Ryan
Rivera, Rafael
Bennett, Crissa
Byrnes, Samantha A.
Connelly, John T.
Dewan, Puneet K.
Boyle, David S.
Weigl, Bernhard H.
Nichols, Kevin P.
Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein
title Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein
title_full Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein
title_fullStr Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein
title_full_unstemmed Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein
title_short Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein
title_sort antibody screening results for anti-nucleocapsid antibodies toward the development of a lateral flow assay to detect sars-cov-2 nucleocapsid protein
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482319/
https://www.ncbi.nlm.nih.gov/pubmed/34608447
http://dx.doi.org/10.1021/acsomega.1c01253
work_keys_str_mv AT catedavidm antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT bishopjoshuad antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT hsiehhelenv antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT glukhovaveronikaa antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT alonzoluisf antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT hermanskyhgleda antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT barrioslopezbrianda antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT grantbenjamind antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT andersoncaitline antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT spencerethan antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT kuhnsamantha antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT gallagherryan antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT riverarafael antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT bennettcrissa antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT byrnessamanthaa antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT connellyjohnt antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT dewanpuneetk antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT boyledavids antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT weiglbernhardh antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein
AT nicholskevinp antibodyscreeningresultsforantinucleocapsidantibodiestowardthedevelopmentofalateralflowassaytodetectsarscov2nucleocapsidprotein